Company Overview and News

LBC sets aggressive goal of 100 new stores a year until 2020

2018-07-09 bworldonline
LBC Express Holdings, Inc. plans to open 100 stores per year until 2020, while embarking on a three-year program that will digitize its core logistics businesses.

LBC acquires 4 cargo, remittance firms

2018-06-28 bworldonline
LBC EXPRESS Holdings, Inc. (LBC) on Thursday said it is acquiring four remittance and cargo companies, which offer LBC services in Australia and Singapore.

LBC acquires remittance, cargo firms abroad

2018-06-28 bworldonline
LBC Express Holdings, Inc. has acquired remittance and cargo companies based in Singapore and Australia with the goal of upping its global revenue.

Asia urged to reduce pricey oil dependency as crude hits $80

SINGAPORE/MUMBAI/MANILA – The cost of Asia’s growing thirst for oil will surpass $1 trillion this year, about twice as much as in 2015 and 2016, as oil prices touch $80 per barrel and continental demand hits a record.

LBC nets P541M

Logistics group LBC Express Holdings saw a 145-percent year-on-year surge in attributable net profit amounting to P541.36 million in the first quarter.

LBC Express revives follow-on offering

2018-04-12 bworldonline
LBC Express Holdings, Inc. has moved to jump-start anew a long-delayed plan to undertake a follow-on offering to fund its expansion program.

LBC Express acquires 2 more logistics firms

2018-03-20 bworldonline
LBC EXPRESS Holdings, Inc. (LBC) is propping up its logistics business with the acquisition of two firms with a combined value of more than P300 million.

LBC boosts logistics backbone

Logistics provider LBC Group has boosted its logistics backbone with the acquisition of an affiliate digital solutions company and a strategic investment in a freight forwarding, cargo handling and management company.

LBC acquires two logistics firms

2018-03-20 bworldonline
LBC Express Holdings, Inc. (LBC) is propping up its logistics business with the acquisition of two firms on Tuesday, March 20, valued at a total of more than P300 million.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PSE:LBC / LBC Express Holdings, Inc. on message board site Silicon Investor.

Global Crossing (GLBC) Global Crossing (GLBC) Global Crossing (GLBC)